# NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

> **NCT07278492** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Down Syndrome (DS)

## Interventions

- **DRUG:** MIB-626
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07278492
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07278492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07278492, "NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07278492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*